Hu, Xiaowei
Logan, Jeongok G.
Kwon, Younghoon
Lima, Joao A. C.
Jacobs, David R.
Duprez, Daniel
Brumback, Lyndia
Taylor, Kent D.
Durda, Peter
Johnson, W. Craig
Cornell, Elaine
Guo, Xiuqing
Liu, Yongmei
Tracy, Russell P.
Blackwell, Thomas W.
Papanicolaou, George
Mitchell, Gary F.
Rich, Stephen S.
Rotter, Jerome I.
Van Den Berg, David J.
Chirinos, Julio A.
Hughes, Timothy M.
Garrett-Bakelman, Francine E.
Manichaikul, Ani
Funding for this research was provided by:
NIH/NHLBI (R01-HL153248)
National Institutes of Health (grants U01-TR003734, U01-TR003734-01S1, UO1-HL160277, R33-HL-146390, R01-HL153646, K24-AG070459, R01-AG058969, R01-HL157108, R01-HL155599, R01-HL104106, R01HL155764)
Article History
Received: 29 June 2023
Accepted: 12 October 2023
First Online: 17 October 2023
Competing interests
: Dr. Chirinos has recently consulted for Bayer, Fukuda-Denshi, Bristol-Myers Squibb, JNJ, Edwards Life Sciences, Merck, and NGM Biopharmaceuticals. He received University of Pennsylvania research grants from National Institutes of Health, Fukuda-Denshi, Bristol-Myers Squibb, Microsoft and Abbott. He is named as inventor in a University of Pennsylvania patent for the use of inorganic nitrates/nitrites for the treatment of Heart Failure and Preserved Ejection Fraction and a patent application for the use of plasma and urine biomarkers in heart failure with preserved ejection fraction. He has received payments for editorial roles from the American Heart Association, the American College of Cardiology, Elsevier and Wiley. He has received research device loans from Atcor Medical, Fukuda-Denshi, Unex, Uscom, NDD Medical Technologies, Microsoft and MicroVision Medical. Other authors declare no conflicts of interests.